Insights into mechanisms underlying the gut and airways modulatory effects of Swertia chirata

Indian Medicinal Plants and Formulations and Their Potential Against COVID-19-Preclinical and Clinical Research

The cases of COVID-19 are still increasing day-by-day worldwide, even after a year of its first occurrence in Wuhan city of China. The spreading of SARS-CoV-2 infection is very fast and different from other SARS-CoV infections possibly due to structural differences in S proteins. The patients with severe diseases may die due to acute respiratory distress syndrome (ARDS) caused by systemic inflammatory reactions due to the excessive release of pro-inflammatory cytokines and chemokines by the immune effector cells. In India too, it is spreading very rapidly, although the case fatality rate is below 1.50% (https://www.statista.com), which is markedly less than in other countries, despite the dense population and minimal health infrastructure in rural areas. This may be due to the routine use of many immunomodulator medicinal plants and traditional AYUSH formulations by the Indian people. This communication reviews the AYUSH recommended formulations and their ingredients, routinely used medicinal plants and formulations by Indian population as well as other promising Indian medicinal plants, which can be tested against COVID-19. Special emphasis is placed on Indian medicinal plants reported for antiviral, immunomodulatory and anti-allergic/anti-inflammatory activities and they are categorized for prioritization in research on the basis of earlier reports. The traditional AYUSH medicines currently under clinical trials against COVID-19 are also discussed as well as furtherance of pre-clinical and clinical testing of the potential traditional medicines against COVID-19 and SARS-CoV-2. The results of the clinical studies on AYUSH drugs will guide the policymakers from the AYUSH systems of medicines to maneuver their policies for public health, provide information to the global scientific community and could form a platform for collaborative studies at national and global levels. It is thereby suggested that promising AYUSH formulations and Indian medicinal plants must be investigated on a priority basis to solve the current crisis.

Phytochemistry and Pharmacological Activities of the Genus Swertia (Gentianaceae): A Review

Swertia plants have been considered to be medicinal plants useful for the treatment of various ailments for thousands of years, especially in Asian countries. This is due to the broad variety of chemical compounds that provide multiple ligands for bonding to different endogenous biomacromolecules for patients. Chemical constituents and pharmacological activities of Swertia plants are summarized in this paper. Approximately 419 metabolites and 40 bioactive compounds have been reported from 30 Swertia species, including xanthones, flavonoids, seco-iridiods, iridiods, triterpenoids, alkaloids, volatiles, and other secondary metabolites. The bioactivities of Swertia plants include anticarcinogenic, hepatoprotective, anti-oxidant, hypoglycemic, anthelmintic, antibacterial, antifungal, anti-diabetic, gut, and airways modulatory, metabolizing isozymes inhibitory, neuroprotective, HIV-I reverse transcriptases inhibitory, anticholinergic, and CNS-depressant activities, etc. In addition, biosynthetic pathways of xanthones, and seco-iridiods, two most important secondary metabolites for Swertia, are elucidated. The xanthones biosynthetic pathway is a mixed biosynthetic pathway involved the shikimate and the malonate routes, and the seco-iridoid pathway starts with geraniol derived from IPP which is produced either via the MEP or the MVA pathway. This review will offer a reference for future researches on the protection of natural resources, the investigation of therapeutic basis, new drug development, and so forth. Metabolic pathways of some crucial active compounds were also discussed in this review.

Natural Products Useful in Respiratory Disorders: Focus on Side-Effect Neutralizing Combinations

This review summarizes literature related to medicinal plants reputed in traditional medical systems for treatment of asthma and coughs. The plants that are pharmacologically investigated for their effectiveness in such conditions, along with respective experimental protocol details, are also discussed. Some of plant origin compounds, which are considered useful as antitussive and antiasthmatic agents, are described as well. Chrysoeriol, a constituent of Aspalathus linearis (Fabaceae) was observed to be selective for relaxant effect in airways (through K⁺ channel activation), compared with other smooth muscles. We reported that Hypericum perforatum (Hyperieaceae), Andropogon muricatus (Poaceae), Juniper excelsa (Coniferae) and Nepeta cataria (Lamiaceae) exhibit bronchodilatory action, mediated through combination of Ca⁺⁺ antagonist and phospohodiesrase inhibitory mechanisms, which scientifically explains their medicinal use in asthma. Hyocyamus niger (Solanaceae), Artemisia vulgaris (Compositae), Fumaria parviflora (Fumariaceae) and Terminalia bellerica (Combretaceae) caused bronchodilation via dual blockade of muscarinic receptors and Ca⁺⁺ influx. Acorus calamus (Araceae), Carum roxburghianum (Apiaceae), Lens culinaris (Fabaceae) and Lepidium sativum (Cruciferae) mediate bronchodilatation through multiple pathways: anticholinergic and inhibition of Ca⁺⁺ channels and PDE enzyme(s). In conclusion, this review presents an analysis of different novel combinations of pharmacological activities in medicinal plants with side effect-neutralizing/synergistic potential, setting new trends in the therapeutic options for hyperactive respiratory disorders such as asthma and cough. Copyright © 2015 John Wiley & Sons, Ltd.